Frequency of adverse events Up to 15 years [clinicaltrials_resource:aaa6b4b25b3bd2d7b082e426e300bde1]
Evaluated by the frequency and relationship of dose-limiting toxicities, if any, experienced by patients during dose escalation.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Frequency of adverse events Up to 15 years [clinicaltrials_resource:aaa6b4b25b3bd2d7b082e426e300bde1]
Evaluated by the frequency and relationship of dose-limiting toxicities, if any, experienced by patients during dose escalation.
Bio2RDF identifier
aaa6b4b25b3bd2d7b082e426e300bde1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:aaa6b4b25b3bd2d7b082e426e300bde1
measure [clinicaltrials_vocabulary:measure]
Frequency of adverse events
time frame [clinicaltrials_vocabulary:time-frame]
Up to 15 years
description
Evaluated by the frequency and ...... tients during dose escalation.
identifier
clinicaltrials_resource:aaa6b4b25b3bd2d7b082e426e300bde1
title
Frequency of adverse events Up to 15 years
@en
type
label
Frequency of adverse events Up ...... 6b4b25b3bd2d7b082e426e300bde1]
@en